Pharma

What happened : Stock underperformed in August amid brokerage downgrade and U.S. policy noise; recall Sun’s US oncology push (Checkpoint deal) earlier this year. Why it matters: Global policy headlines can hit Indian pharma near-term despite long-term pipelines. Beginner takeaway: Separate noise vs. narrative—track pipeline milestones and valuations.